Frazier Life Sciences Management’s Tarsus Pharmaceuticals TARS Stock Holding History

Frazier Life Sciences Management’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$45.9M	Hold	728,644	–	–	1%	22
2026 Q1	$51.1M	Hold	728,644	–	–	1.32%	18
2025 Q4	$59.7M	Sell	728,644 -438,883	-38%	-$32.8M	1.6%	17
2025 Q3	$69.4M	Sell	1,167,527 -230,000	-16%	-$11.3M	2.08%	12
2025 Q2	$56.6M	Hold	1,397,527	–	–	2.26%	10
2025 Q1	$71.8M	Sell	1,397,527 -190,000	-12%	-$9.39M	3.28%	8
2024 Q4	$87.9M	Hold	1,587,527	–	–	3.65%	10
2024 Q3	$52.2M	Hold	1,587,527	–	–	2.09%	15
2024 Q2	$43.1M	Sell	1,587,527 -200,000	-11%	-$6.72M	2.02%	15
2024 Q1	$65M	Hold	1,787,527	–	–	2.74%	11
2023 Q4	$36.2M	Hold	1,787,527	–	–	1.94%	15
2023 Q3	$31.8M	Hold	1,787,527	–	–	2.11%	13
2023 Q2	$32.3M	Hold	1,787,527	–	–	1.93%	13
2023 Q1	$22.5M	Hold	1,787,527	–	–	1.63%	17
2022 Q4	$26.2M	Hold	1,787,527	–	–	1.63%	15
2022 Q3	$30.6M	Hold	1,787,527	–	–	2.36%	12
2022 Q2	$26.1M	Buy	1,787,527 +370,370	+26%	+$5.56M	2.46%	12
2022 Q1	$23.8M	Buy	+1,417,157	New	+$26.3M	2.03%	15

Other funds holding TARS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Frazier Life Sciences Management's TARS Position: Q2 2026 in Review

Frazier Life Sciences Management held its Tarsus Pharmaceuticals (TARS) position steady in Q2 2026 at 728,644 shares worth $45.9M. The position accounts for 1% of the portfolio, ranked #22.

Frazier Life Sciences Management first reported a position in TARS in Q1 2022 and has held it in 18 quarters since. The position peaked at $87.9M in Q4 2024. 256 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

Frazier Life Sciences Management held 728,644 shares of Tarsus Pharmaceuticals worth $45.9M as of Q2 2026.
Frazier Life Sciences Management left its Tarsus Pharmaceuticals share count unchanged in Q2 2026.
Tarsus Pharmaceuticals made up 1% of Frazier Life Sciences Management's portfolio in Q2 2026, its #22 holding.
Frazier Life Sciences Management first reported a position in Tarsus Pharmaceuticals in Q1 2022 and has held it in 18 quarters since.
Frazier Life Sciences Management's Tarsus Pharmaceuticals position peaked at $87.9M in Q4 2024.
256 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Frazier Life Sciences Management's 13F filing for Q2 2026, filed 14 Aug 2026.